Patents by Inventor Stephen L. Gwaltney, II

Stephen L. Gwaltney, II has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and uses thereof for the modulation of hemoglobin
    Patent number: 9957250
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 1, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Jason R. Harris, Zhe Li, Stephen L. Gwaltney, II
  • Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
    Patent number: 9802900
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 31, 2017
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Stephen L. Gwaltney, II, Jason R. Harris
  • Pyrazolopyridine pyrazolopyrimidine and related compounds
    Patent number: 9695166
    Abstract: In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: July 4, 2017
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Chul Yu, Calvin Yee, Stephen L. Gwaltney, II, Brian W. Metcalf, Steven Richards, Matthew A. Lardy, Lina Setti, Hing Sham
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160332984
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: December 28, 2015
    Publication date: November 17, 2016
    Inventors: Brian W. Metcalf, Jason R. Harris, Zhe Li, Stephen L. Gwaltney, II
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160083343
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: March 24, 2016
    Applicant: Global Blood Therapeutics, Inc
    Inventors: Qing XU, Zhe LI, Stephen L. GWALTNEY, II
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160046613
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: February 18, 2016
    Applicant: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Brian W. METCALF, Zhe LI, Qing XU, Stephen L. GWALTNEY, II, Jason R. HARRIS, Calvin W. YEE
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160031865
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: February 4, 2016
    Applicant: Global Blood Therapeutics, Inc.
    Inventors: Zhe LI, Qing XU, Brian W. METCALF, Stephen L. GWALTNEY, II, Jason R. HARRIS, Calvin W. YEE
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160031904
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: February 4, 2016
    Applicant: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Zhe LI, Qing XU, Brian W. METCALF, Stephen L. GWALTNEY, II, Jason R. HARRIS, Calvin W. YEE
  • COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20160024127
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 28, 2016
    Applicant: Global Blood Therapeutics, Inc.
    Inventors: Jason R. HARRIS, Brian W. METCALF, Zhe LI, Stephen L. GWALTNEY, II
  • PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS
    Publication number: 20150315198
    Abstract: In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X1, L1, L3, and R3 are described herein.
    Type: Application
    Filed: May 4, 2015
    Publication date: November 5, 2015
    Applicant: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Chul Yu, Calvin Yee, Stephen L. Gwaltney,, II, Brian W. Metcalf, Steven Richards, Matthew A. Lardy, Lina Setti, Hing Sham
  • BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
    Publication number: 20150259296
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 17, 2015
    Inventors: Zhe Li, Stephen L. Gwaltney, II, Jason R. Harris
  • Compounds and uses thereof for the modulation of hemoglobin
    Publication number: 20140274961
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Jason R. Harris, Zhe Li, Stephen L. Gwaltney, II
  • Dipeptidyl Peptidase Inhibitors
    Publication number: 20110087022
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: wherein E is CH or N, Q is selected from the group consisting of CO, CS, SO, SO2, or C?NR4, and L, X, Z, R2 and R3 are as defined herein.
    Type: Application
    Filed: December 9, 2010
    Publication date: April 14, 2011
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7872124
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: wherein E is CH or N, Q is selected from the group consisting of CO, CS, SO, SO2, or C?NR4, and L, X, Z, R2 and R3 are as defined herein.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: January 18, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7790736
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: September 7, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7723344
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: May 25, 2010
    Assignee: Takeda San Diego, Inc.
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7678909
    Abstract: Compounds are provided which may be used to inhibit DPP-IV comprising the formula: wherein the substituents are as described in the specification and claims.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: March 16, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Laurence E. Burgess, Scott D. Cowen, Stephen L. Gwaltney, II, Jeongboeb Seo, Jeffrey A. Stafford
  • Dipeptidyl peptidase inhibitors
    Patent number: 7579357
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: August 25, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhlyuan Zhang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7470700
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: December 30, 2008
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • Farnesyltransferase inhibitors
    Patent number: 7323570
    Abstract: Substituted imidazoles and thiazoles having the formula are useful for inhibiting farnesyltransferase. Also disclosed are farnesyltransferase-inhibiting compositions and methods of inhibiting farnesyltransferase in a patient.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: January 29, 2008
    Assignee: Abbott Laboratories
    Inventors: Akiyo K. Claiborne, Stephen L. Gwaltney, II, Lisa A. Hasvold, Qun Li, Tongmei Li, Nan-Horng Lin, Robert A. Mantei, Todd W. Rockway, Hing L. Sham, Gerard M. Sullivan, Yunsong Tong, Gary Wang, Le Wang, Xilu Wang, Wei-Bo Wang